Share on LinkedInShare on LinkedIn

ARTICLE · 24 DECEMBER 2025

Interpreting Section 3(d) Of The Patents Act On Therapeutic Efficacy

S.S. Rana & Co.
S.S. Rana & Co.
Contributor
S.S. Rana & Co.

S.S. Rana & Co.

Established in 1989, S.S. Rana & Co. is a premier intellectual property and corporate law firm...

View firm profile
Explore more from S.S. Rana & Co.

In the recent case of Zeria Pharmaceutical Co. Ltd vs The Controller of Patents, an appeal was filed by the Zeria Pharmaceutical Co. Ltd, before the Delhi High Court against the refusal order by the Assistant Controller of Patents & Designs ("Learned Controller" hereafter).

IndiaIntellectual Property

Introduction:

In the recent case ofZeria Pharmaceutical Co. Ltd vs The Controller of Patents,anappeal was filed by the Zeria Pharmaceutical Co. Ltd, before the Delhi High Court against the refusal order by the Assistant Controller of Patents & Designs ("Learned Controller" hereafter). The Zeria Pharmaceutical Co. Ltd ("Appellant" hereafter) filed an Indian Patent Application no. 3630/DLNP/2011 ("Subject Application" hereafter) as a divisional application from the Parent Indian Patent Application No. 1090/DELNP/2007, claiming novel intermediate compound formula (5a) on the ground of grounds of lack of inventive step (Section 2(1)(ja)) and non-patentability under Section 3(d).

This case specifically addresses the interpretation and application of Section 3(d) of the Patents Act, 1970, that the slight modification of structure of known pharmaceutical intermediates compound must exhibits enhance therapeutic efficacy to be patentable under Section 3(d) of the Indian

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from